Science
EORTC
EORTC/X

Why Patient Quality of Life Must Be Central in Advanced Cancer Trials – EORTC

European Organisation for Research and Treatment of Cancer (EORTC) shared a post on X:

“New in The Lancet Oncology:

Policy review led by Ian Tannock and Madeline Pe with EORTC and Common Sense Oncology underscores why patient quality of life must be central in advanced cancer trials.

Read More.”

Title: Importance of responder criteria for reporting health-related quality-of-life data in clinical trials for advanced cancer: recommendations of Common Sense Oncology and the European Organisation for Research and Treatment of Cancer

Authors: Ian F Tannock, Madeline Lee Pe, Christopher M Booth, Michael Brundage, Nathan I Cherny, Corneel Coens, Elizabeth A Eisenhauer, Jan Geissler, Johannes M Giesinger, Bishal Gyawali, Sjoukje F Oosting, Gregory R Pond, Jaap C Reijneveld, Enrique Soto-Perez-de-Celis, Michelle Tregear, Winette T A van der Graaf

Read The Full Article at The Lancet Oncology.

Why Patient Quality of Life Must Be Central in Advanced Cancer Trials - EORTC

More posts featuring EORTC on OncoDaily.

Bishal Gyawali cancer Christopher M. Booth Common Sense Oncology Corneel Coens Elizabeth A. Eisenhauer Enrique Soto Perez de Celis EORTC Gregory R Pond Ian F. Tannock Ian Tannock Jaap C Reijneveld Jan Geissler Johannes M Giesinger Madeline Lee Pe Madeline Pe Michael Brundage Michelle Tregear Nathan I Cherny OncoDaily Oncology Sjoukje F Oosting Winette T.A. van der Graaf